• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Royalty Pharma (RPRX) Higher Revenue Lower Profit

    Simply Wall St·11/11/2026 23:47:14
    Listen to the news
    • Royalty Pharma reported third quarter 2026 revenue of US$690.1 million and net income of US$144.68 million, with basic and diluted EPS from continuing operations of US$0.32.
    • An interesting detail for investors is the contrast between higher revenue and lower earnings. This highlights the pressure on Royalty Pharma’s profitability despite growing top line receipts.
    • We will now see how Royalty Pharma's higher revenue but weaker net income shapes the investment narrative built around royalty cash flows.

    Scan how Royalty Pharma's earnings pattern compares with other cash generative plays by reviewing our hand picked list of solid balance sheet and fundamentals (24 results).

    Royalty Pharma Investment Narrative Recap

    For a shareholder in Royalty Pharma, the core belief is that a diversified royalty portfolio on marketed and late stage therapies can support durable cash generation, even as individual products ebb and flow. The latest quarter, with revenue of US$690.1 million but net income of US$144.68 million and EPS of US$0.32, puts the focus firmly on profitability, not just receipts.

    The analyst consensus Narrative on Simply Wall St leans on future earnings growth and returns on equity improving from today’s levels. In the short term, a key factor is how quickly management can translate higher portfolio receipts into cleaner margins. The biggest near term risk is capital intensive deals that do not offset royalty disputes or development setbacks.

    The most relevant fresh data point is the same earnings release for the nine months to September 30, 2026. Revenue of US$1,994.82 million alongside net income of US$457.25 million shows that the pattern of higher top line and softer earnings is not confined to a single quarter, which matters if you care about cash conversion and debt capacity.

    That backdrop feeds straight into the existing catalysts in the analyst consensus Narrative on Simply Wall St. A larger pipeline of 19 development stage therapies and deployment targets of US$2b to US$2.5b each year only help shareholders if future royalty receipts come through strongly enough to support margins, service a high debt load and offset product or trial disappointments.

    Royalty Pharma's analyst narrative projects US$4.5b revenue and US$1.8b earnings by 2029, which implies 20.0% yearly revenue growth and an earnings increase of about US$1.1b from US$672.5m today.

    Uncover why Royalty Pharma's fair value is essentially in line with its current price.

    NasdaqGS:RPRX 1-Year Stock Price Chart
    NasdaqGS:RPRX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate Royalty Pharma story leans heavily on the R&D co funding push as a positive swing factor. The most optimistic analysts were pencilling in about US$4.8b of revenue and US$3.2b of earnings by 2029 before this quarter’s weaker profitability. You can use this latest report to test how firmly you still agree with that brighter scenario.

    Explore 3 other Royalty Pharma fair value estimates, including one that suggests there could be as much as 197% upside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

    Looking For More Investment Ideas Beyond Royalty Pharma?

    Fresh insight often comes from comparing Royalty Pharma with other businesses that share some of its strengths, whether that is balance sheet resilience, income potential, or a mix of quality and value. Use the Simply Wall St Screener to widen your watchlist and pressure test your thesis against a broader set of opportunities.